<![CDATA[HCW9302, HCW Biologics’ IL-2Rα-Biased Fusion Immunotherapeutic, Shows Preliminary Clinical Activity in Phase 1 Alopecia Areata Trial with Favorable Early Safety Profile]]>
Tuesday, June 16, 2026View original
Read the full article on the original site.
Read Full Article